HMG (Human Menopausal Gonadotropin / Menotropins)
FSH / LH-active gonadotropin · heavily regulated
Overview
Human Menopausal Gonadotropin (HMG, generic name Menotropins) is a mixed FSH and LH gonadotropin preparation purified from the urine of postmenopausal women, where elevated pituitary gonadotropins are excreted in concentrated form due to the loss of ovarian feedback inhibition. The historical material is a roughly 1:1 mixture of FSH and LH biological activity per IU and is approved for ovulation induction and assisted reproductive technology workflows under brand names including Menopur, Repronex, and several biosimilars. HMG occupies a distinct position in the gonadotropin category because the dual FSH+LH activity supports both follicular development and luteal-phase support, in contrast to recombinant FSH-only preparations (Gonal-F, Follistim) that require co-administration of an LH source. Lyochem distributes HMG only to qualified buyers with appropriate licensing for assisted-reproductive or compounding workflows in their destination jurisdiction. The 75 IU standard fill is the historical convention matching the classical Menopur ampoule format. As with HCG, the release packet emphasizes biological activity (FSH IU + LH IU per ampoule by bioassay) rather than chemical purity alone, the urine-derived source means the material is a mixed glycoprotein population rather than a defined single molecule.
Who buys this, and why
Other research peptides in this category — Melanotan-1, Melanotan-2, PT-141, ACE-031, Adipotide-FTTP, EPO, HCG, HMG — ship to research labs studying topics outside the GH / cognitive / immune / mitochondrial / repair / longevity / Khavinson clusters. Each peptide has its own analytical-packet emphasis (e.g. glycoprotein bioassay in IU/mg for HCG; cyclised-form confirmation for oxytocin) noted in the per-product CoA scope.
Primary buyer fit: research laboratories that have validated this peptide into their workflow and regional research-supplier partners and university-block resellers.
Specifications
- CAS
- 9002-68-0
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 75 IU
- MOQ
- On request
- Lead time
- 21–45 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Counter-ion analysis (where applicable)
- Solubility / reconstitution guidance
- Bacterial endotoxin (LAL) on request — in vivo workflows
Regulatory note
Highly regulated urine-derived gonadotropin biological. Sold only to qualified buyers with appropriate licensing in their jurisdiction. Order requires compliance review.
Frequently asked questions
What's the difference between HMG and recombinant FSH (Gonal-F, Follistim)?▾
HMG is a urine-derived mixed-gonadotropin preparation containing both FSH and LH activity in roughly 1:1 ratio per IU. Recombinant FSH preparations (Gonal-F, Follistim) contain only FSH activity, with no LH component. The clinical consequence is that HMG supports both follicular development (FSH-driven) and luteal-phase progesterone production (LH-driven) within a single product, whereas recombinant FSH protocols typically require separate LH-source administration (LH activity from HCG or recombinant LH) during the luteal phase. The choice between HMG and recombinant FSH depends on the specific assisted-reproductive-technology protocol, patient population, and prescriber preference. Both are widely used and supported by extensive clinical data.
Why is HMG still widely used despite being a urine-derived rather than recombinant product?▾
Urinary-derived HMG (under brand names Menopur, Repronex, and biosimilars) has been used clinically since the 1950s with extensive accumulated safety and efficacy data. The recombinant alternatives are more recent (1990s onwards) and offer the theoretical advantage of higher-purity material with consistent batch composition, but the clinical-outcome differences in most published comparison studies are modest. The urinary-derived preparations also have economic advantages, sourcing from postmenopausal-women urine remains less expensive per IU than recombinant cell-culture production. Many assisted-reproductive-technology centers continue to use HMG protocols specifically because of the depth of accumulated experience with the urinary-derived preparation.
How is the 75 IU standard fill used in typical assisted-reproductive-technology protocols?▾
The 75 IU HMG ampoule format is the historical clinical-dose unit, sized to match the typical daily injection dose in ovulation-induction protocols. A standard IVF cycle might use 1-4 ampoules (75-300 IU) per daily dose, titrated to the patient's follicular response measured by ultrasound and serum estradiol. Total cycle exposure typically runs 8-14 days at 1-4 ampoules per day before the HCG trigger injection that induces final follicular maturation. The 75 IU fill format predates and influenced the broader gonadotropin-injection ecosystem, most clinics' inventory management and dosing protocols are built around this unit size, which is why even when alternative formats are available the 75 IU ampoule remains the workhorse.
Related peptides